Anti-Rheumatic Drugs - Bosnia and Herzegovina

Bosnia and Herzegovina

The projected revenue in the Anti-Rheumatic Drugs market in Bosnia and Herzegovina is expected to reach US$4.29m in 2024.
It is anticipated that the revenue will show an annual growth rate (CAGR 2024-2028) of 0.69%, leading to a market volume of US$4.41m by 2028.
In a global comparison, United States is expected to generate the highest revenue, amounting to US$37,550.00m in 2024.
Bosnia and Herzegovina's anti-rheumatic drugs market is experiencing a rise in demand due to an aging population and an increasing prevalence of rheumatic diseases.

Key regions: France, Italy, Brazil, China, India

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Bosnia and Herzegovina has been experiencing significant growth in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis and other related conditions are increasingly seeking effective treatments to alleviate their symptoms. As such, there is a growing demand for Anti-Rheumatic Drugs in Bosnia and Herzegovina.

Trends in the market: One trend that has been observed in the Anti-Rheumatic Drugs market in Bosnia and Herzegovina is the increasing popularity of biologic drugs. These drugs are made from living cells and are highly effective in treating rheumatoid arthritis and other related conditions. Additionally, there has been a shift towards self-injectable drugs, which offer greater convenience for patients.

Local special circumstances: Bosnia and Herzegovina has a relatively high prevalence of rheumatoid arthritis and other related conditions. This has contributed to the growth of the Anti-Rheumatic Drugs market in the country. Additionally, the government has been taking steps to improve access to healthcare for its citizens, which has further boosted demand for these drugs.

Underlying macroeconomic factors: The economic situation in Bosnia and Herzegovina has been improving in recent years, which has led to increased healthcare spending. This has contributed to the growth of the Anti-Rheumatic Drugs market in the country. Additionally, the country's accession to the European Union has led to greater regulatory harmonization, which has made it easier for pharmaceutical companies to bring their products to market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.